CN104771430B - For treating the medicine of intestinal irritable syndrome - Google Patents
For treating the medicine of intestinal irritable syndrome Download PDFInfo
- Publication number
- CN104771430B CN104771430B CN201510167793.0A CN201510167793A CN104771430B CN 104771430 B CN104771430 B CN 104771430B CN 201510167793 A CN201510167793 A CN 201510167793A CN 104771430 B CN104771430 B CN 104771430B
- Authority
- CN
- China
- Prior art keywords
- elecampane
- application according
- ibs
- rat
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of medicine for being used to treat intestinal irritable syndrome of tcm field, wherein total lactone of inula helenium L content>70%, and wherein alantolactone, isoalantolactone content account for more than the 90% of total lactones.The present invention has improvement gastrointestinal tract dynamia and analgesic characteristic well using total lactone of inula helenium L, it is and curative for effect to gastrointestinal function sexual dysfunction, screened by pharmacological testing and determine that total lactone of inula helenium L has a better effect diarrhea-type and constipation-predominant of irritable bowel syndrome (IBS) tool, can significantly alleviate IBS symptoms.
Description
Technical field
The present invention relates to a kind of technology of the field of Chinese medicines, is specifically that one kind is used to treat intestinal irritable syndrome (IBS)
Medicine.
Background technology
Irritable bowel syndrome is common disease of digestive system, with abdominal pain or abdominal discomfort, is changed with defecation character, custom
Become the intestinal dysfunction syndrome being characterized, lack the foundation of morphology and biochemical marker exception.IBS is common disease, popular
Disease learns investigation and shows in healthy population have 10%~20% once to suffer from this disease, and IBS patient accounts for Gastroenterology dept. and sees a doctor number
More than 50%.It was expected that most people once suffered from IBS in life at it.The disease is the 2nd kind after common cold tight
Ghost image rings the common disease of people's work and quality of life.Once it was referred to as " allergic colitis ", " easily swashing colitis " or " mucus
Property colitis ", etiology and pathogenesis is still not clear, it has been suggested that have social psychological behavior, heredity, infection and immune, food and medicine
Thing factor etc..But all these theories fail to explain the various performances of IBS completely, so now it is believed that IBS
The cause of disease is the result of multifactor interaction.Modern medicine there is no special effect medicine therapeutic to irritable bowel syndrome at present, although western
Medicine to IBS have it is certain the effect of, but side effect be also it will be apparent that and persistence and stability it is still immature.And the traditional Chinese medical science
Chinese medicine is treated by dialectical treatmert, or using specific prescription and medication, or with the methods of acupuncture, massage, and curative effect is stablized, and toxic side effect
It is small, thus clinically there is some superiority.Traditional Chinese medicine to unique curative effect of IBS, and a large amount of experiences accumulated in terms for the treatment of,
It is worth further research, exploitation.
Elecampane (Radix Inulae) is the traditional Chinese medicine in China, is composite family Inulaplants elecampane (Inula
Helenium L.) dry root.Autumn excavates, and removes silt, dries.Acrid flavour, hardship, it is warm-natured.Return liver, the spleen channel.With invigorating the spleen and
The effect of stomach, promoting the flow of qi and relieving stagnancy, analgesic tocolysis.For treat sternal rib, abdominal distention, vomiting dysentery, sternal rib dampen, feel a pain in the chest when breathing have a pain,
Fetal irritability.Main product is in Hebei, Zhejiang, Sichuan, Henan, Shanxi, Shaanxi, Gansu and Xinjiang and other places.Ancient rome era, people are just
Using elecampane as medicine and food.For a long time, it is good warming and tonifying agent, can treat the breathing such as chronic bronchitis system
System disease.Elecampane is time-honored pest repellant, its anthelmintic action is better than santonin, and toxicity is relatively low.Its antibacterial action
It is one of Major Clinical application, has preferable suppression to tubercle bacillus, Pseudomonas aeruginosa, staphylococcus aureus, dermatophyte etc.
Make and use.Elecampane can effectively control heart rate, reduce blood pressure and blood glucose, be clinically used for the treatment of angiocardiopathy.Radia heleii
Methanolic extract also there is stronger antiproliferative effect to stomach cancer cell, uterine cancer cells.
Elecampane is also one of Ji Yuan of Tibetan medicine-Tibet inula root.Tibet inula root, the entitled agate of Tibetan medicine is exerted or Ma Nubazha
(Manupatra), have and stomach tocolysis, qi-regulating and other effects, for treating the diseases such as chronic gastritis, gastrointestinal dysfunction；《Brilliant pearl
Book on Chinese herbal medicine》、《Tibetan medicine and pharmacology is selected and compile》With《Ask language silver mirror》In it is on the books.As conventional Chinese medicine, especially common Tibetan medicine and anaesthetic it
One, elecampane is used in national proved recipe extensively, and records in 2010 editions pharmacopeia, cures mainly the diseases such as indigestion.Elecampane is to stomach and intestine
Road functional disorder is curative for effect, and research is found, elecampane can adjust Intestinal transit and secretion；It is high to gastrointestinal smooth muscle
There is inhibitory action during concentration, there is excitation in when low concentration.In addition elecampane is the natural painkiller thing of no dependence, analgesia effect
Fruit is no different with analgin, just there is traditional effect of strengthening the spleen and stomach, regulating qi-flowing for relieving pain since ancient times.Elecampane compound preparation such as Six-element is pacified
Dissipation, Sophara Flavescens Ait etc. have been used clinically for improving gastroenteritic power exception and pain, and achieve preferable treatment
Effect.This prompting elecampane may have the effect of certain to the irritable bowel syndrome characterized by intestinal smooth dyskinesia,
Specific pharmacodynamics and pharmacokinetic studies work needs further to be carried out.In addition, elecampane requires growth conditions width and is adapted to
Chinese most places cultivation.Medicine source is wide, and price is low, few side effects, curative for effect using wide.It can be further separated in the future
Active ingredient, strengthens pharmacological research, provides science reference for clinical practice, develops the new drug of high-efficiency low-toxicity.
Found by the retrieval to the prior art, Chinese patent literature CN101380348 discloses (bulletin) day
2009.03.11, a kind of extracting method for being used to promote the Radix Inulae extract of WeiDongLi Capsule of technical field of traditional Chinese medicines, bag are disclosed
Include CO2- supercritical extraction and ethanol extraction method, CO2- supercritical extraction：The root of elecampane or total shape banksia rose is ground into
Coarse powder, sieving, is fitted into supercritical extraction reactor, is passed through CO2Supercritical extract is carried out, extract is released from separating still.Ethanol
Extraction method：The root of elecampane or total shape banksia rose is ground into particle, ethanol is added, is heated to reflux, extracting solution lets cool filtering, subtracts
Push back and receive ethanol to no alcohol taste；It is uniform that residue with petroleum ether and column chromatography silica gel mixes sample, is added on silica gel capital, uses oil
Ether-acetone gradient elution, Fractional Collections merge alantolactone or the more fraction of isoalantolactone, recycling solvent to the greatest extent,
Up to Radix Inulae extract.The Radix Inulae extract that the technology extracts, which can be applied, is preparing the medicine for the treatment of gastric dynamic dysfunction
In.But the Radix Inulae extract that the technology is obtained does not relate to whether there is treatment IBS activity, in addition, the technology provides
A kind of extracting method for preparing the Radix Inulae extract comprising alantolactone and isoalantolactone, belongs to crude extract；And
It is unstable that the preparation method obtains crude extract composition, and is not suitable for large-scale industrial production.
The content of the invention
The present invention is directed to deficiencies of the prior art, proposes a kind of medicine for being used to treat intestinal irritable syndrome,
Have the characteristics that to improve gastrointestinal tract dynamia and analgesic activities well using elecampane chloroform extract total lactone of inula helenium L, be applied to
The treatment of gastrointestinal function sexual dysfunction.The present invention is screened by pharmacological testing determines total lactone of inula helenium L to diarrhea-type and constipation type
Irritable bowel syndrome (IBS) tool has a better effect, and can significantly alleviate IBS symptoms.
The present invention is achieved by the following technical solutions：
The present invention relates to a kind of medicine for being used to treat intestinal irritable syndrome, active ingredient is total lactone of inula helenium L, it contains
Amount is more than 70% (wt).
The sum of content of alantolactone, isoalantolactone accounts for the 90% of total lactones in the total lactone of inula helenium L
(wt) more than.
The alantolactone and the structural formula of isoalantolactone are respectively：
The total lactone of inula helenium L is isolated from composite family Inulaplants elecampane.
The medicine is used but is not limited to：Oral enteric coated preparations, such as capsulae enterosolubilis, enteric coatel tablets or enteric-coated micro-pill.
Be used to treat the preparation methods of IBS medicines the present invention relates to a kind of, by by medicinal extract made of elecampane through silica gel
The solute obtained after column chromatography is dried under reduced pressure to obtain.
The medicinal extract, is soaked in solvent by elecampane dry powder and is heated to reflux obtaining.
The elecampane dry powder refers to：The coarse powder that dry elecampane root crushed after being dried obtains.
The solvent is preferably ethanol, and the immersion refers to：Concentration is used to be soaked for 70~95% (v/v) ethanol solutions
6~24h is steeped, its dosage is 8~12 times of amounts (v/w).
It is described be heated to reflux during it is small using the ethanol solution reflux 1~3 of 70-95% (v/v) when.
The silica gel column chromatography uses the silica gel of 100-200 mesh particle diameters, its dosage is：Alantol medicinal extract：Silica gel 1：2
~1：3(w/w)；Chromatographic column blade diameter length ratio is 1：2~1：5；Eluant, eluent forms：Petroleum ether：Acetone (100：2~100：4, v/v)；
Eluting agent is：Every gram of medicinal material uses 10mL~14mL eluant, eluents.
Brief description of the drawings
Fig. 1 is rat difference pellet morphology percentage comparisons schematic diagram in 1 diarrhea-type IBS each groups of embodiment；
Fig. 2 rat difference pellet morphology percentage comparisons schematic diagrames between 1 diarrhea-type IBS each groups of embodiment；
Fig. 3 withdraws reflection scoring schematic diagram for 1 diarrhea-type IBS each group rat abdomens of embodiment；
Fig. 4 is 1 diarrhea-type IBS each group rat blood serum NO content schematic diagrames of embodiment；
Fig. 5 is 1 diarrhea-type IBS each group rat blood serum 5-HT content schematic diagrames of embodiment；
Fig. 6 is 1 diarrhea-type IBS each group rat colon tissue VIP content schematic diagrames of embodiment；
Fig. 7 is rat 14d and 19d stool interval comparison schematic diagram in 2 constipation type IBS each groups of embodiment；
Fig. 8 rat 14d and 19d stool interval comparison schematic diagrams between 2 constipation type IBS each groups of embodiment；
Fig. 9 is rat 14d and 19d excrement water content comparison schematic diagram in 2 constipation type IBS each groups of embodiment；
Figure 10 rat 14d and 19d excrement water content comparison schematic diagrams between 2 constipation type IBS each groups of embodiment；
Figure 11 withdraws reflection scoring schematic diagram for 2 constipation type IBS each group rat abdomens of embodiment；
Figure 12 is 2 constipation type IBS each group rat blood serum NO content schematic diagrames of embodiment；
Figure 13 is 2 constipation type IBS each group rat blood serum 5-HT content schematic diagrames of embodiment；
Figure 14 is 2 constipation type IBS each group rat colon tissue VIP content schematic diagrames of embodiment.
Embodiment
Elaborate below to the embodiment of the present invention, the present embodiment is carried out lower premised on technical solution of the present invention
Implement, give detailed embodiment and specific operating process, but protection scope of the present invention is not limited to following implementation
Example.
Embodiment 1
The present embodiment prepares a kind of medicine for treating irritable bowel syndrome, and effective ingredient (contains for total lactone of inula helenium L
Amount>70%), wherein alantolactone and isoalantolactone account for more than the 90% of total lactones.
Said medicine active ingredient is prepared into oral formulations；Oral formulations are enteric coated tablet, capsulae enterosolubilis or enteric are micro-
Ball.
Said medicine preparation method comprises the following steps：
1) dry elecampane root crushed after being dried into coarse powder and is first used into alcohol solution dipping；
2) medicinal material after immersion is heated to reflux simultaneously recycling design, up to alantol medicinal extract；
3) alantol medicinal extract is subjected to silica gel column chromatography and collects eluent；
4) solvent after silica gel column chromatography in gained is collected, and wherein solute will obtain purity after being dried under reduced pressure and be more than
More than 90% total lactones highly finished product；
The immersion refers to：Concentration is used as 70~95% (v/v) 6~24h of alcohol solution dipping, its dosage for 8~
12 times of amounts (v/w)；
It is described be heated to reflux during it is small using the ethanol solution reflux 1~3 of 70-95% (v/v) when；
The silica gel column chromatography refers to：Using the silica gel of 100-200 mesh particle diameters, its dosage is：Alantol medicinal extract：Silicon
Glue 1：2~1：3(w/w)；Chromatographic column blade diameter length ratio is 1：2~1：5；Eluant, eluent forms：Petroleum ether：Acetone (100：2~100：4,
v/v)；Eluting agent is：Every gram of medicinal material uses 10mL~14mL eluant, eluents.
The medicine of the above-mentioned treatment irritable bowel syndrome being prepared is carried out diarrhea irritable bowel syndrome by the present embodiment
The therapeutic effect detection of rat, it is specific as follows：
Experimental animal：Male Wistar rat, 260~340g of weight.
Trial drug：
Test 1 group：1.8mg/mL Pinaverium Bromides suspension (positive drug)
Test 2 groups：1mg/mL total lactone of inula helenium L emulsion (low dosage alantolactone)
Test 3 groups：3mg/mL total lactone of inula helenium L emulsion (middle dosage alantolactone)
Test 4 groups：9mg/mL total lactone of inula helenium L emulsion (high dose alantolactone)
Test apparatus：Electronic analytical balance；Electronic weighing scale；Interior cut type high-speed homogenization machine；Ultraviolet-uisible spectrophotometer；
Full wavelength scanner formula microplate reader；Miniature high-speed refrigerated centrifuge；Low speed large capacity Multi-pipe centrifugal machine；Electric heating constant temperature sink；Ultrasound
Ripple cleaning machine.
Test method：Rat is grouped at random, each group fasting for solids but not liquids 24h.Rat is after ether light anesthesia, from anus
6-Fr double lumen catheters (away from anus 8cm) are inserted into, in addition to blank control group, the acetic acid solution of 1mL 4% is injected, makes it in colon
Interior retention 30s.Then each group injection 1mL phosphate buffers rinse colon, slowly extract catheter, put back to freely activity in cage
Feed drinking-water.Each group gives different pharmaceutical, and model group and blank group gavage the sodium carboxymethyl cellulose solution of same volume, 1 time/
D, common 5d.7d observes each group stress in rats defecation situation.Each group Rat Fast 24h can't help water, ether light anesthesia before experiment
Afterwards, Head And Face is scratched with wide adhesive tape constraint crop, preepipodite and chest, limitation preepipodite, but does not limit its activity.It is placed on
In metabolic cage, taken out after fettering 1h.Respectively the hard just points of record, soft stool points, it is shapeless just count, and calculate percentage.Row
Just after testing, belly withdrawal reflex scoring is carried out to each group rat.Rat crosses band air bag after ether light anesthesia, by rinse
6Fr double lumen catheters per anum insertion (make air bag end insertion anus in 5cm, rat is fixed at 1cm outside anus
Root of the tail portion), rat is put into in special transparent plastic box (18cm × 5cm × 7cm), can only move forward and backward to turn round, and treat
Rat starts to test after adapting to environment 30min.Every rat gives balloon expandable 5 times, capacity is respectively 0.4,0.6,0.8,
1.0th, 1.5mL, every time expansion continue 4min, interval 30s (to prevent Intestinal ischemia).Stomach wall withdraws reflection (Abdominal with-
Drawal reflex, AWR) standards of grading：0 point, when giving Colon and rectum expansion stimulates, rat mood is basicly stable；1 point, give
Become unstable during stimulation, twist head once in a while；2 points, abdomen muscle of back slight shrinkage but belly is not lifted away from ground；3 points, the abdomen back of the body
Portion's muscle is stronger to be shunk and belly is lifted away from ground；4 points, abdominal muscles strong contraction, belly is arched and belly, perineum
Portion is lifted away from ground.8d gathers each group rat blood serum, and each group rat is through chloraldurate (10% normal saline solution, dosage
After 300mg/kg) anaesthetizing, abdominal cavity is splitted, sustainer takes a blood sample 8-10mL in vacuum blood collection tube pipe, stands 20min, 3600rpm/
Min centrifuges 10min, and Aspirate supernatant, stores after packing in less than -20 DEG C refrigerators, kit detection serum NO and 5-HT.The
After 8d blood samplings, the colon of clip each group rat 8cm from caecum lower end.Colon is rinsed in ice-cold physiological saline, is removed
Remove top layer connective tissue and internal layer blood, excrement, filter paper wipe it is dry after, weigh 0.2g and be placed in 10mL centrifuge tubes.Precision measures
The physiological saline of 1.8mL precoolings is ground into 10% up and down as homogenate medium with interior cut type tissue refiner 15000rpm/min
Tissue homogenate (Homogenization time 10s/ times, gap 30s, continuous 3 times, carries out in frozen water).4 DEG C of centrifugations of 3000rpm/min
After 10min, the chloroform for adding 1/2 supernatant volume removes high lipid material, 4 DEG C of centrifugation 10min of 10000rpm/min, in absorption
Clear liquid, stores after packing in less than -20 DEG C refrigerators, kit detection colon VIP.
Result of the test：
1 diarrhea-type IBS each group rat average weight growth rates of table compare (%)
As shown in Figure 1, illustrate for rat difference pellet morphology percentage comparisons effect in diarrhea-type IBS each groups, in figure：*P
<0.05, * * P<0.01, * * * P<0.001 with hard just percentage ratio.
As shown in Fig. 2, rat difference pellet morphology percentage comparisons effect is illustrated between diarrhea-type IBS each groups, in figure：*P
<0.05, * * P<0.01 with blank group ratio；#P<0.05 with model group ratio.
Illustrate as shown in figure 3, withdrawing reflection scoring effect for diarrhea-type IBS each group rat abdomens, in figure：**P<0.01 with
Blank group ratio；#P<0.05, ##P<0.01 with model group ratio.
As shown in figure 4, illustrate for diarrhea-type IBS each group rat blood serum NO contents effect, in figure：**P<0.01 and blank group
Than；#P<0.05, ##P<0.01 with model group ratio.
As shown in figure 5, illustrate for diarrhea-type IBS each group rat blood serum 5-HT contents effect, in figure：***P<0.001 with it is empty
White group ratio；###P<0.001 with model group ratio.
As shown in fig. 6, illustrate for diarrhea-type IBS each group rat colon tissue VIP contents effect, in figure：***P<0.001
With blank group ratio；#P<0.05, ###P<0.001 with model group ratio.
According to above-mentioned experimental data as it can be seen that the present embodiment passes through to diarrhea-type irritability syndrome (D-IBS) rat defecation
Situation, belly withdraw the observation of reflection, and regulate and control lower neurotransmitter and gastrointestinal hormone (NO, 5-HT, VIP) to brain-gut axis
Assay finds that this medicine can significantly reduce the loose stool rate of D-IBS rats, improves pain threshold, and up-regulation rat NO is horizontal, under
Adjust 5-HT horizontal, lower VIP levels, there is preferable therapeutic effect to D-IBS.
Embodiment 2
The medicine of the treatment irritable bowel syndrome of different content is prepared using method same as Example 1 for the present embodiment
Thing, and its therapeutic effect to constipation type intestinal irritable syndrome rat is detected, it is specific as follows：
Experimental animal：Male Wistar rat, 120~150g of weight.
Trial drug：
Test 1 group：1.8mg/mL Pinaverium Bromides suspension (positive drug)
Test 2 groups：1mg/mL total lactone of inula helenium L emulsion (low dosage alantolactone)
Test 3 groups：3mg/mL total lactone of inula helenium L emulsion (middle dosage alantolactone)
Test 4 groups：9mg/mL total lactone of inula helenium L emulsion (high dose alantolactone)
Test apparatus：Electronic analytical balance；Electronic weighing scale；Interior cut type high-speed homogenization machine；Ultraviolet-uisible spectrophotometer；
Full wavelength scanner formula microplate reader；Miniature high-speed refrigerated centrifuge；Low speed large capacity Multi-pipe centrifugal machine；Electric heating constant temperature sink；Ultrasound
Ripple cleaning machine.
Test method：Rat is grouped at random, each group rat divides cage individually to raise, to eliminate the influence of biological rhythm,
In 13:00 starts gavage, drinking-water of normally ingesting before and after each group gavage.14d, 19d collect each group rat excrement, each group rat
It is placed in metabolic cage, collects 3-18h excrement, record excrement points.The excrement particles of taking-up are placed in 10mL centrifuge tubes, are recorded
Excrement initial mass.80 DEG C of vacuum decompression dryings record excrement final mass to constant weight.20d carries out belly withdrawal reflex and comments
Point, blood was collected to each group rat by 21d, and it is to be measured to leave and take colon.The scoring of belly withdrawal reflex, serum NO and 5-
VIP content detections are the same as experiment 1 in HT, colon.
Result of the test：
As shown in fig. 7, illustrate for rat 14d and 19d stool interval comparative effectiveness in constipation type IBS each groups, in figure：**P<
0.01 with 14d ratios.
As shown in figure 8, rat 14d and 19d stool interval comparative effectiveness is illustrated between constipation type IBS each groups, in figure：***P
<0.001 with blank group ratio；###P<0.001 with model group ratio.
As shown in figure 9, for rat 14d and 19d excrement water content comparative effectiveness signal in constipation type IBS each groups, scheme
In：***P<0.001 with 14d ratios.
As shown in Figure 10, rat 14d and 19d excrement water content comparative effectiveness is illustrated between constipation type IBS each groups, figure
In：***P<0.001 with blank group ratio；###P<0.001 with model group ratio.
As shown in figure 11, withdraw reflection scoring effect for constipation type IBS each group rat abdomens to illustrate, in figure：**P<
0.01, * * * P<0.001 with blank group ratio；#P<0.05, ##P<0.01, ###P<0.001 with model group ratio.
As shown in figure 12, illustrate for constipation type IBS each group rat blood serum NO contents effect, in figure：**P<0.01 and blank
Group ratio；#P<0.05, ##P<0.01 with model group ratio.
As shown in figure 13, illustrate for constipation type IBS each group rat blood serum 5-HT contents effect, in figure：***P<0.001 with
Blank group ratio；###P<0.001 with model group ratio.
As shown in figure 14, illustrate for constipation type IBS each group rat colon tissue VIP contents effect, in figure：***P<0.001
With blank group ratio；#P<0.05, ###P<0.001 with model group ratio.
According to above-mentioned experimental data as it can be seen that the present embodiment passes through to constipation-predominant of irritable bowel syndrome (C-IBS) rat defecation
Situation, belly withdraw the observation of reflection, and regulate and control lower neurotransmitter and gastrointestinal hormone (NO, 5-HT, VIP) to brain-gut axis
Assay finds that this medicine can dramatically increase the stool interval and excrement water content of C-IBS rats, reduces pain threshold, under
Mouse NO levels are tuned up, lower 5-HT levels, VIP levels is lowered, there is preferable therapeutic effect to C-IBS.
Claims (8)
1. a kind of application of total lactone of inula helenium L, it is characterised in that be used to prepare treatment diarrhea-type irritability syndrome and constipation
The oral enteric coated preparations of type irritable bowel syndrome, the active ingredient of the enteric coated preparations is total lactone of inula helenium L, its content is 70%
(wt) more than, the sum of content of alantolactone, isoalantolactone accounts for the 90% of total lactones in total lactone of inula helenium L therein
(wt) more than, wherein：The structural formula of alantolactone and isoalantolactone is respectively：、。
2. application according to claim 1, it is characterized in that, the total lactone of inula helenium L is isolated from the plant of composite family Inula
Thing elecampane.
3. application according to claim 1, it is characterized in that, the enteric coated preparations are capsulae enterosolubilis, enteric coatel tablets or enteric
Pellet.
4. application according to claim 1, it is characterized in that, the enteric coated preparations are by the way that medicinal extract made of elecampane is passed through
The solute obtained after silica gel column chromatography is dried under reduced pressure to obtain；
The medicinal extract, is soaked in solvent by elecampane dry powder and is heated to reflux obtaining.
5. application according to claim 4, it is characterized in that, the elecampane dry powder refers to：Dry elecampane root
The coarse powder that crushed after being dried obtains.
6. application according to claim 4, it is characterized in that, the immersion refers to：Concentration is used as 70 ~ 95% (v/v) second
Alcoholic solution soaks 6 ~ 24 h, its dosage is 8 ~ 12 times of amounts (v/w).
7. application according to claim 4, it is characterized in that, it is described be heated to reflux during using 70-95%'s (v/v)
When ethanol solution reflux 1 ~ 3 is small.
8. application according to claim 4, it is characterized in that, the silica gel column chromatography uses the silicon of 100-200 mesh particle diameters
Glue, its dosage are：Alantol medicinal extract：Silica gel 1：2~1：3(w/w)；Chromatographic column blade diameter length ratio is 1：2~1：5；Eluant, eluent forms：
Petroleum ether：Acetone 100：2~100：4 (v/v)；Eluting agent is：Every gram of medicinal material uses the mL eluant, eluents of 10 mL ~ 14.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510167793.0A CN104771430B (en) | 2015-04-10 | 2015-04-10 | For treating the medicine of intestinal irritable syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510167793.0A CN104771430B (en) | 2015-04-10 | 2015-04-10 | For treating the medicine of intestinal irritable syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104771430A CN104771430A (en) | 2015-07-15 |
| CN104771430B true CN104771430B (en) | 2018-05-08 |
Family
ID=53613417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510167793.0A Active CN104771430B (en) | 2015-04-10 | 2015-04-10 | For treating the medicine of intestinal irritable syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104771430B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973554A (en) * | 2012-12-19 | 2013-03-20 | 上海中医药大学 | Medical application of alantolactone |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1587482A4 (en) * | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | Anti-inflammatory compositions and uses thereof |
-
2015
- 2015-04-10 CN CN201510167793.0A patent/CN104771430B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973554A (en) * | 2012-12-19 | 2013-03-20 | 上海中医药大学 | Medical application of alantolactone |
Non-Patent Citations (2)
| Title |
|---|
| 土木香内酯与异土木香内酯的提取与纯化工艺;张乐等;《天然产物研究与开发》;20150131;第27卷(第1期);对比文件1摘要、结论 * |
| 炎症性肠病与肠易激综合征的相关性研究进展;杨华丽等;《国际消化病杂志》;20141031;第34卷(第5期);第299页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104771430A (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102085252B (en) | Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof | |
| CN104013668B (en) | Licoflavone class extract is used to prepare to be applied in treatment ulcerative colitis medicine | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN101161251A (en) | On-off total saponin as well as its extracting method and application | |
| CN108888670B (en) | Colon targeting capsule for treating ulcerative colitis and preparation process thereof | |
| CN102526164A (en) | Traditional Chinese medicine composition for preventing insulin resistance and related metabolic syndrome thereof | |
| WO2011035734A1 (en) | Relinqing extract, preparative method and use thereof | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN102342970A (en) | Wild chrysanthemum extract as well as preparation method and use of same | |
| CN104983814B (en) | A kind of Radix Pulsatillae extract and its application in prevention pulmonary fibrosis medicine is prepared | |
| CN105343260B (en) | The drug for treating chronic ulcerative colitis | |
| CN101011545A (en) | Method for extracting effective sites group of smilax China root | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN102389496B (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN1994352B (en) | Use of total glucosides extract of cocklebur fruit in preparation of product for resisting inflammatory reaction | |
| CN104771430B (en) | For treating the medicine of intestinal irritable syndrome | |
| CN109662967A (en) | A kind of antidepressant and application thereof | |
| CN102228666B (en) | Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease | |
| CN101129972A (en) | Traditional Chinese medicine composition, preparation method and use of the same | |
| CN109419787A (en) | A kind of purposes of Diterpene class compound | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN108601804A (en) | Composition for preventing and treating inflammatory bowel disease | |
| CN103893286B (en) | It is a kind of to treat Chinese medicine preparation of chronic renal disease and preparation method thereof | |
| CN105497167A (en) | New application of radix ranunculi ternati in preparation of medicine for treating and/or preventing ulcerative colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |